90 related articles for article (PubMed ID: 27072223)
1. Exploring the mechanism of non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitor.
Yu Y; Luo Y; Zheng Y; Zheng X; Li W; Yang L; Jiang J
J Cancer Res Ther; 2016; 12(1):121-5. PubMed ID: 27072223
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Wu X
Gene; 2018 Feb; 643():74-82. PubMed ID: 29221754
[TBL] [Abstract][Full Text] [Related]
3. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
[TBL] [Abstract][Full Text] [Related]
4. Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells.
Saygideğer-Kont Y; Minas TZ; Jones H; Hour S; Çelik H; Temel I; Han J; Atabey N; Erkizan HV; Toretsky JA; Üren A
Neoplasia; 2016 Feb; 18(2):111-20. PubMed ID: 26936397
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
[TBL] [Abstract][Full Text] [Related]
8. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
12. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
15. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Li R; Hu Z; Sun SY; Chen ZG; Owonikoko TK; Sica GL; Ramalingam SS; Curran WJ; Khuri FR; Deng X
Mol Cancer Ther; 2013 Oct; 12(10):2200-12. PubMed ID: 23894143
[TBL] [Abstract][Full Text] [Related]
16. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
17. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry-based secretome analysis of non-small cell lung cancer cell lines.
Bosse K; Haneder S; Arlt C; Ihling CH; Seufferlein T; Sinz A
Proteomics; 2016 Nov; 16(21):2801-2814. PubMed ID: 27569058
[TBL] [Abstract][Full Text] [Related]
19. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
[TBL] [Abstract][Full Text] [Related]
20. Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.
Zhou X; Liu B; Ning Q; Xia Z; Zhong R; Zhang L; Wu L
Oncol Rep; 2021 Jan; 45(1):217-229. PubMed ID: 33200228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
